Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo

Mohammad A. Esmaeili1,†,‡, Shilpi Yadav1,†, Ravi Kr. Gupta2, Garrett R. Waggoner1, Abigail Deloach1, Noel Y. Calingasan3, M. Flint Beal3 and Mahmoud Kiaei1,*

1Department of Neurobiology and Developmental Sciences, Center for Translational Neuroscience and, 2Department of Microbiology and Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, 72205 AR, USA and 3Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA

*To whom correspondence should be addressed. Tel: +1 5015265638; Fax: +1 5015265678; Email: mkiae@uams.edu; kiaeim@yahoo.com

Abstract

Neuroinflammation, immune reactivity and mitochondrial abnormalities are considered as causes and/or contributors to neuronal degeneration. Peroxisome proliferator-activated receptors (PPARs) regulate both inflammatory and multiple other pathways that are implicated in neurodegeneration. In the present study, we investigated the efficacy of fenofibrate (Tricor), a pan-PPAR agonist that activates PPAR-α as well as other PPARs. We administered fenofibrate to superoxide dismutase 1 (SOD1G93A) mice daily prior to any detectable phenotypes and then animal behavior, pathology and longevity were assessed. Treated animals showed a significant slowing of the progression of disease with weight loss attenuation, enhanced motor performance, delayed onset and survival extension. Histopathological analysis of the spinal cords showed that neuronal loss was significantly attenuated in fenofibrate-treated mice. Mitochondria were preserved as indicated by Cytochrome c immunostaining in the spinal cord, which maybe partly due to increased expression of the PPAR-γ co-activator 1-α. The total mRNA analysis revealed that neuroprotective and anti-inflammatory genes were elevated, while neuroinflammatory genes were down-regulated. This study demonstrates that the activation of PPAR-α action via fenofibrate leads to neuroprotection by both reducing neuroinflammation and protecting mitochondria, which leads to a significant increase in survival in SOD1G93A mice. Therefore, the development of therapeutic strategies to activate PPAR-α as well as other PPARs may lead to new therapeutic agents to slow or halt the progression of amyotrophic lateral sclerosis.

Introduction

Neurodegenerative diseases, spinal cord injury, multiple sclerosis and fetal alcohol syndrome toxicity all have common pathological hallmarks, including neuroinflammation and mitochondrial dysfunction. Understanding these underlying mechanisms and how to prevent or reverse them will facilitate the disease management and therapeutic discovery. Among the neurodegenerative diseases, amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular and neurodegenerative disorder in which neuroinflammation and mitochondrial dysfunction are a common denominator. ALS largely affects the motor cortex, brainstem, spinal cord and neurons, which innervate skeletal muscles. Currently, the only FDA-approved drug for ALS is Riluzole, which prolongs life-expectancy...
by 3–6 months; hence, the discovery of an effective therapeutic strategy is an urgent, unmet medical need.

In a recent study, peroxisome proliferator-activated receptor (PPAR)-α is regulated hepatic autophagy in mice (1), and also induced PPAR-γ co-activator 1-α (PGC-1α) (2). Mitochondrial dysfunction in ALS has gained ample evidence with mitochondrial DNA instability and deletion, and consistent identification of missense mutations in the CHCHD10 gene for ALS (3). Mitochondria and important cellular organelles like the endoplasmic reticulum are critical for the intracellular Ca2+ pool and proper cellular function, and mutations in the VAPB protein that have been linked to ALS (4) increase the importance of regulating these pathways (5).

Peroxisome proliferator-activated receptors and their utility for the treatment of neurodegenerative diseases

The PPARs are ligand-modulated transcription factors with three known isoforms: PPAR-α, PPAR-β or PPAR-δ and PPAR-γ. PPAR-α is mostly expressed in the brain, liver, heart, kidney, brown adipose tissue and skeletal muscle (6,7). PPAR/β/δ is robustly expressed in the cerebellum, medulla oblongata, hypothalamus, cerebral cortex and spinal cord (6). PPAR-γ has high-expression levels in brown and white adipose tissues, brain, colon, differentiated myeloid cells and the placenta (9,10). PPARs play major roles in the regulation of gene-expression programs of metabolic pathways (11). Natural PPAR ligands are primarily unsaturated fatty acids (derivatives of linolenic acid, eicosanoids and components of oxidized LDLs); synthetic ligands include fibrates and thiazolidinediones. The binding of ligands to PPARs results in dissociation of co-repressors from the PPAR/retinoid X receptor (RXR) complex and recruitment of transcriptional co-activators, including PGC-1α, enhancing energy metabolism and mitochondrial biogenesis. PPARs regulate multiple pathways from metabolism to immune responses (11–17). The activation of PPARs has anti-inflammatory effects that are beneficial in several mouse models of neurodegenerative diseases including ALS (18–21), tauopathy (tau) (22), Huntington’s disease (HD) (23), experimental autoimmune encephalomyelitis, (24) and Parkinson’s disease (PD) (25). These studies suggest that specific isoforms of PPARs and their preferential activation may have utility in treating neurodegenerative diseases. The above cited studies, and our study described in this manuscript, demonstrate that the activation of PPARs regulates an array of genes to reduce inflammation. PPAR activation also reduces oxidative stress and blocks microglial activation, as well as enhancing mitochondrial biogenesis and function. We and others showed that the activation of PPAR-γ resulted in clinical efficacy in superoxide dismutase 1 (SOD1G93A) mice (20,21). The activation of PPAR-α has been shown to increase the expression of PGC-1α and to induce autophagy by increasing the expression of transcription factor EB, a master gene for lysosomal biogenesis. We therefore examined whether fenofibrate, a pan-PPAR agonist with predominant activity at PPAR-α, can either block or slow the progression of neurodegeneration in the SOD1G93A transgenic mouse model of ALS.

Results

PPAR activation improves ALS-like phenotypes and extends survival

Two cohorts of SOD1G93A mice were administered fenofibrate (n = 15, 7 males and 8 females) at 200 mg/kg/day or vehicle (n = 14, 7 males and 7 females) beginning at postnatal day 40 (p40) by intraperitoneal injection and analyzed for body weight, motor performance, pathology and survival.

Weight loss analysis

Weight changes were monitored from p60 and found SOD1G93A mice begin losing weight that coincided with the age of disease onset at approximately p85–p90. The weight loss was attenuated in the fenofibrate-treated cohort (Fig. 1A). The weight difference was significant between these groups at P < 0.01 (t-test).

Motor performance analysis

Fenofibrate or vehicle-treated SOD1G93A mice were studied for motor performance with rotarod testing twice per week. SOD1G93A mice in the vehicle group showed shorter latency to fall from the rotating rod at a constant speed of 12 rpm. The constant speed paradigm is the most commonly used for ALS mice and is the best suited approach to determine the differences between treated and untreated SOD1G93A mice. The accelerated paradigm is not suitable to differentiate the difference at the later stage of disease in this model. Fenofibrate-treated SOD1G93A mice had a longer latency to fall off the 12 rpm rotating rod from p90 onward (Fig. 1B). The performance difference was significant between these groups at P < 0.01 (t-test).

Survival analysis

Generally, the average survival age in SOD1G93A mice in our colony is 128 ± 5 days. In this experiment, the average survival age for the fenofibrate-treated SOD1G93A mice was increased to 138 ± 5 (n = 15) days, while the vehicle-treated group average survival age was 127 ± 3.4 days (n = 14). This is an increase of 11 days (8.7%), [log-rank (Mantel–Cox) P-value < 0.0001] (Fig. 1C). The mean and median of survival ages in fenofibrate-treated group were 138 and 140 days, respectively. In dimethyl sulfoxide (DMSO)-treated control group, mean and median survival ages are 127, and 128 days, respectively (Table 1). This unpaired t-test has a P-value of <0.0001, which is considered extremely significant.

The overall age of the onset of ALS in fenofibrate-treated SOD1G93A mice delayed from 85 to 88 days to 100 days based on the rotarod and weight data (Fig. 1A and B).

Attenuation of spinal neuronal cell loss with PPAR-α activation

Two cohorts of SOD1G93A mice (n = 6/cohort, equal in males and females) were treated with fenofibrate or vehicle (DMSO). Fully symptomatic disease stage mice were sacrificed at 110 days of age for spinal cord motor neuron analysis. Approximately, 50% of spinal neurons have degenerated at this stage of disease. The unbiased stereological neuronal cell count software system was used to count Nissl-stained lumbar neurons in the spinal cord sections. There was a significant attenuation of neuronal loss in the fenofibrate-treated mice relative to vehicle-treated cohort (Fig. 2).

Spinal cord gliosis is reduced by PPAR activation

Lumbar spinal cord sections from SOD1G93A mice treated with fenofibrate or vehicle at P110 were stained with a marker of microglia, CD11b (cluster of differentiation molecule 11b) (Fig. 3A), and marker of astrocytes, GFAP (glial fibrillary acidic protein) (Fig. 3B). Both CD11b and GFAP immunoreactivities were diminished in fenofibrate-treated SOD1G93A mice compared.
with untreated mice, suggesting a reduction in microglial activation and gliosis due to PPAR-\(\alpha\) activation (Fig. 3).

**PPAR activation reduces Cytochrome c release from mitochondria and increases PGC-1\(\alpha\) in the spinal cord**

Cytochrome c and PGC-1\(\alpha\) are important molecules for mitochondria. Cytochrome c (a pro-apoptotic factor and a marker for trigger of apoptosis from the intrinsic pathway) if released from mitochondria will initiate apoptosis. Cytochrome c levels and release from mitochondria in the spinal cord were examined in 110-day-old SOD1\(^{G93A}\) mice treated with either fenofibrate or vehicle. The results show intense, punctate Cytochrome c immunoreactivity around the nuclei of neurons of fenofibrate-treated mice, while immunostaining was reduced in vehicle-treated SOD1\(^{G93A}\) mice (Fig. 4A). This suggests that fenofibrate blocked the release of Cytochrome c from the mitochondria of motor neurons in the spinal cord. To examine the effect of PPAR-\(\alpha\) activation on PGC-1\(\alpha\), a mitochondrial biogenesis factor, the lumbar spinal cord sections of 110-day-old fenofibrate- or vehicle-treated SOD1\(^{G93A}\) mice were immunostained with an antibody against PGC-1\(\alpha\). It was found that immunostaining was increased in the spinal cord motor neurons in fenofibrate-treated mice, when compared with vehicle-treated controls (Fig. 4B). These results show that fenofibrate up-regulates PPAR-\(\alpha\), blocks the release of Cytochrome c from the mitochondria and further up-regulates the expression of an array of genes to subdue multiple pathological hallmarks of ALS. Specifically, an increase in the expression of PGC-1\(\alpha\), which is known to increase mitochondrial biogenesis and expression of antioxidant enzymes, was observed.

**PPARs up-regulate key neuroprotective genes**

To assay for elevation in neuroprotective genes under the regulation of activated PPARs, the total mRNA level isolated from spinal cords of SOD1\(^{G93A}\) mice treated with fenofibrate or vehicle (\(n = 5\)) were examined. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using cDNA synthesized from total RNA. PPARs (PPAR-\(\alpha\), PPAR-\(\beta/\delta\) and PPAR-\(\gamma\)) mRNA levels were increased and PGC-1\(\alpha\), nuclear respiratory factor-1, transcription factor A mitochondrial (Tfam), Sirtuin 1 (SIRT1) and Sirtuin 3 (SIRT3) were significantly increased upon fenofibrate treatment. The expression of antioxidant genes such as NAD(P)H dehydrogenase quinoneoxidoreductase-1 (NQO-1) and hemeoxygenase-1 (HO-1) were restored in fenofibrate-treated mice. The mRNA for genes that produce proteins suppressor of cytokine signaling-1 (SOCS-1) and suppressor of cytokine signaling-3

---

**Table 1. Mean and median values**

<table>
<thead>
<tr>
<th>SOD1(^{G93A}) mice</th>
<th>Mean</th>
<th>Median (50%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fenofibrate treated ((n = 15))</td>
<td>138</td>
<td>140</td>
</tr>
<tr>
<td>Control (DMSO) treated ((n = 14))</td>
<td>127</td>
<td>128</td>
</tr>
<tr>
<td>The two-tailed P-value</td>
<td>&lt;0.0001, extremely significant</td>
<td></td>
</tr>
<tr>
<td>t-value</td>
<td>6.737 with 27 degree of freedom</td>
<td></td>
</tr>
</tbody>
</table>

---

Figure 1. Fenofibrate-induced PPAR activation effects on body weight, muscle strength and survival. Body weight (A) and motor performance (B) analysis of vehicle (\(n = 14\)) and fenofibrate-treated mice (\(n = 15\) per group). Body weight difference between treated and vehicle groups was significantly different between the ages of 105–125 days, \(P < 0.01\). Motor performance using a rotarod apparatus rotating at constant speed of 12 rpm and latency to fall from the rotating rod (max 180s) was assessed and there was a significant difference observed between the ages of 95–130 days, \(P < 0.01\). (C) The Kaplan–Meier survival curve of G93A mice treated with fenofibrate showing cumulative survival of fenofibrate-treated and vehicle-control mice with a statistical significant extension at \(P < 0.0001\).
(SOCS-3) were also increased several fold after fenofibrate treatment. We also checked the mRNA level of glycogen synthase kinase-3β (GSK3β), which is a serine/threonine protein kinase which is known to phosphorylate PPAR-α. No significant change was found in GSK3β levels in the spinal cords of mice treated with fenofibrate. Although, in this study, there was no investigation of phosphorylated GSK3β, another study with bezafibrate consistently showed no alteration in total GSK3β (22). The activation of PPARs is known to inhibit the transcriptional regulation of many key inflammatory genes (26). The elevation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) are indicative of proinflammatory responses. iNOS and COX-2 mRNA and protein levels were quantified after fenofibrate treatment (Figs 5 and 6). iNOS mRNA and protein levels were significantly reduced in fenofibrate-treated SOD1G93A mice in comparison with vehicle-treated mice (Figs 5 and 6). Similarly, COX-2 mRNA and protein levels were decreased in the spinal cords of fenofibrate-treated SOD1G93A mice (Figs 5 and 6). All spinal cord mRNA samples were normalized against GAPDH mRNA (Fig. 5). In protein analysis, β-actin was used as a housekeeping gene (Fig. 6).

**Discussion**

The list of loci, gene candidates and mutated genes linked to familial ALS (fALS) is expanding rapidly. Table 2 summarizes some of the mutations that are being most studied. TANK-binding kinase 1 (TBK1) is a gene with mutation linked to fALS and its protein mobilizes the autophagy and neuroinflammation pathways (41), interacts with optineurin (OPTN), which regulates NF-κB, and is linked to autophagy (42). Whereas SQSTM1 is another ALS gene linked to autophagosome. Since OPTN, SQSTM1 (p62) and TBK1 function in autophagy and are linked to ALS, which they provide evidence for autophagy and neuroinflammation as important pathways in ALS due to protein/RNA aggregation.

The SOD1G93A transgenic mouse, a model based on the human fALS SOD1-linked mutation, has been an effective model to study human ALS. Of all the drugs/compounds that have been tested in the SOD1G93A mouse model, only Riluzole is FDA approved...
Even though there is only modest success, the SOD1-based models are continuing to be used in testing therapeutics for ALS in conjunction with new models being developed. At this point, the testing of therapeutics is mostly limited to mouse and to some extent zebra fish models (46,47). Induced pluripotent stem cell technology, which allows the generation of human fALS motor neurons from skin fibroblasts, is an emerging model for drug testing in many neurodegenerative diseases (48).

Both of our earlier studies, as well as interesting similar findings by others on PPARs (49,50), prompted us to test the efficacy of fenofibrate, a pan PPAR activator, to further investigate the role of the activation of PPARs in neurodegenerative diseases. Since we previously showed that PPAR-γ activation extended life span in a mouse model of motor neuron disease (20), we used the same paradigm to further test the neuroprotective effects of a pan PPAR agonist. Fenofibrate belongs to the broad fibrate class of peroxisome proliferator-receptor activators that mostly act through the α-isomer of PPAR, although it has some activity in both PPAR-γ and δ/β. It is an FDA-approved drug to treat patients with hyperlipidemia, patients with type 2 diabetes, high-cholesterol and high-triglyceride levels. In this manuscript, we present a set of new data showing neuroprotective effects of PPAR activation by fenofibrate in SOD1G93A transgenic mice, as shown in Figure 4.

Figure 4. The effect of fenofibrate treatment on mitochondrial-related proteins in the lumbar spinal cord of SOD1G93A transgenic mice. Cytochrome c (Cyto c) immunostaining is punctate (i.e. intact mitochondria concentrating around the nucleus) in fenofibrate-treated mice. Consistently, PGC1-alpha protein immunoreactivity increased in spinal cord neurons in the SOD1G93A transgenic mice when compared with vehicle-treated controls. The scale bar is 100 microns.

Figure 5. Fenofibrate enhances PPAR-alpha-mediated expression of PPARs: histograms shows the modulation of PPARs regulated genes, i.e. mitochondrial relevant, cytokine signaling suppressing, inflammatory, anti-inflammatory and anti-oxidative genes in the spinal cord of fenofibrate and vehicle-treated SOD1G93A mice. The levels of each gene cDNA was normalized to GAPDH and expressed as fold changes relative to the vehicle-treated controls. *P<0.05, n=5, Student’s t-test. Dotted line drawn at the height of control levels.
using fenofibrate, which prolongs life span in the SOD1G93A transgenic mouse model of motor neuron degeneration.

**Fibrates and their potential to block neurodegeneration**

Fenofibrate preferentially regulates PPAR-α and is a member of the fibrate class of hypolipidemic drugs that have been extensively used to treat hypertriglyceridemia and mixed hyperlipidemia. Fenofibrate is a promising drug for ALS and perhaps other neurodegenerative diseases, because it regulates PPARs, which in turn reduces neuroinflammation and promotes mitochondrial stability. Accumulating evidence supports mitochondrial involvement, and in multiple studies we have shown mitochondrial dysfunction and decreased mitochondrial Ca²⁺ capacity (51), impaired mitochondrial dynamics and bioenergetics (52), increased production of mitochondrial reactive oxygen species and reduced mitochondrial respiration in ALS. There are key studies that convincingly implicate mitochondria as a target of mutant SOD1 toxicity, hence supporting our rationale for using fenofibrate to reduce inflammation, oxidative damage and enhancing mitochondrial function.

**PPARs as targets against neurodegeneration**

PPARs are known to inhibit the expression of inflammatory genes in several models.

These inflammatory genes include: nuclear factor-κB (NF-κB), NF of activated T cells, activator protein 1 and signal transducers and activators of transcription (53). While natural PPAR ligands are primarily unsaturated fatty acids, synthetic ligands including fibrates and thiazolidinediones are being used as drugs. Genes involved in energy metabolism, particularly lipid metabolism, adipocyte differentiation and mitochondrial biogenesis are downstream of PPARs (54–56). Certain PPAR agonists increase mitochondrial oxidative phosphorylation capacity in mouse and human cells (57,58). Sigma receptor 1 (SIGMAR1) mutations were shown to cause mitochondrial dysfunction in a cell model of ALS (59) adding evidence that implicates mitochondrial dysfunction, and providing a rationale that boosting mitochondrial function could benefit ALS patients. Fenofibrate protects against 3-nitropropionic acid, a potent mitochondrial inhibitor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin which cause degeneration of dopaminergic neurons in PD, stroke and traumatic brain injury (60,61). We recently showed that fibrates such as bezafibrate have robust neuroprotective effects in the B6/2 transgenic mouse model of HD. Bezafibrate increased PGC-1α, PPARs and downstream genes, increased the number of mitochondria, improved phenotype and survival, and attenuated neuronal atrophy and astrogliosis (23). In another study using the P301S transgenic mouse model for Tau, bezafibrate treatment significantly improved behavioral deficits, reduced numbers of phospho-tau immunoactive neurons and increased PPAR-α, PPAR-γ, PPAR-β, Tαm, Cytochrome c, ATP synthase, hemoxegenase-1 (HO-1) and glutathione peroxidase 1 (Gpx-1) and both full-length and N-terminal truncated PGC-1α mRNA, showing that multiple pathways were targeted by PPAR activation (22). Another recent study showed that fenofibrate upregulates a class of proteins, cytchrome P450 4Fs (Cyp 4fs) that are involved in detoxification of the potent pro-inflammatory eicosanoid, leukotriene B4 (LTB₄) to 20-hydroxy LTB₄ (62). Bezafibrate enhances lipid metabolism and oxidative capacity in fibroblasts or

![Figure 6. Fenofibrate reduces the expression of inflammatory molecules. Western blot analysis of SOD1G93A control and fenofibrate-treated spinal cord homogenates (30 µg/lane) subjected to polyacrylamide electrophoresis using iNOS, COX-2 antibodies shows significant reduction in iNOS and COX-2. Arbitrary values indicate the densitometry of bands ratios normalized against β-actin.](https://academic.oup.com/hmg/article-abstract/25/2/317/2384652)

**Table 2. List of genes linked to fALS.**

<table>
<thead>
<tr>
<th>Genes</th>
<th>Cellular pathway</th>
<th>Disease genetic linkage</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD1</td>
<td>Aggregation, oxidative stress, mitochondria, ER stress</td>
<td>ALS1</td>
<td>(27)</td>
</tr>
<tr>
<td>Vesicle-associated binding protein</td>
<td>ER stress, mitochondria</td>
<td>ALS</td>
<td>(4)</td>
</tr>
<tr>
<td>Valosin-containing protein</td>
<td>Mitochondria, autophagy</td>
<td>ALS</td>
<td>(28)</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis 2</td>
<td></td>
<td>ALS2</td>
<td>(29)</td>
</tr>
<tr>
<td>Fused in sarcoma/translocated in liposarcoma</td>
<td>Aggregation, RNA metabolism</td>
<td>FTD/ALS</td>
<td>(30)</td>
</tr>
<tr>
<td>Transactive response DNA binding protein</td>
<td>Aggregation, RNA metabolism</td>
<td>FTD/ALS</td>
<td>(31,32)</td>
</tr>
<tr>
<td>Hexanucleotide expansion in chromosome 9 open reading frame 72</td>
<td>RNA ioci, RNA metabolism, aggregation</td>
<td>FTD/ALS</td>
<td>(33,34)</td>
</tr>
<tr>
<td>SIGMAR1</td>
<td>Motor neuron excitability</td>
<td>ALS</td>
<td>(35)</td>
</tr>
<tr>
<td>OPTN</td>
<td>Apoptosis, inflammation</td>
<td>ALS, glaucoma</td>
<td>(36,37)</td>
</tr>
<tr>
<td>Ubiquitin 2</td>
<td>Protein degradation</td>
<td>FTD/ALS</td>
<td>(38)</td>
</tr>
<tr>
<td>Profilin 1</td>
<td>Cytoskeletal</td>
<td>ALS</td>
<td>(39)</td>
</tr>
<tr>
<td>Tubulin-α-4 A</td>
<td>Cytoskeletal, axonal/synaptic pathology</td>
<td>ALS</td>
<td>(40)</td>
</tr>
<tr>
<td>TBK1</td>
<td>NFκB pathway, neuroinflammation</td>
<td>ALS</td>
<td>(41)</td>
</tr>
</tbody>
</table>
myoblasts from patients deficient in mitochondrial complexes I, III and IV (58) and reduces the incidence of myocardial infarction in patients with the metabolic syndrome (63). The effect of fibrates on mitochondria is further supported by the study of Wenz et al. (64), showing that overexpressing PGC-1α produced dramatic increases in survival and motor performance in mice with a genetic deficiency in a Cytochrome c oxidase (COX) subunit. Even more relevant to ALS, a recent study by Cleveland’s group showed that overexpression of PGC-1α in the muscle of SOD1G93A mice improved the quality of life in terms of reduced ALS symptoms, although no increase in survival. They showed increases in mitochondrial biogenesis and activity, retention of muscle function, delayed muscle atrophy and significantly improved muscle endurance even at late disease stages (65). An increase in PGC-1α activity therefore may be an attractive therapy for ALS due to its effect on muscle, which is supported by our present study showing that fenofibrate activates PGC-1α and prevents spinal cord motor neuron death in SOD1G93A mice.

Fenofibrate is considered safe, with few known side-effects. A cautionary note is that fenofibrate, a lipid disorder treating drug, may consequently reduce weight in humans; therefore, this may be a cause for concern for neurologists. There are epidemiological studies, however, that show little evidence of human weight loss with fenofibrate use. In an FDA supported online survey of over 8000 people who used fenofibrate, only 0.3% reported weight loss, which is remarkably low. In our study, the fenofibrate-treated SOD1G93A mice maintained weight more successfully than the transgenic control mice. The results from wild-type (C57BL/6J) mice fed a high fat diet and given fenofibrate, which gained weight equally to a control diet (66). This study suggests that if fenofibrate causes weight loss in some patients, utilization of a high fat diet if cautiously used maybe an alternative approach to mitigate this side-effect. Two important studies regarding nutritional intake and intervention strategies and further substantiated by clinical trial that hypercaloric intake is tolerable and potentially beneficial for ALS patients (67,68). Therefore, when fenofibrate is considered for clinical testing, nutritional intake and intervention strategies should be added to the clinical trial design.

**Conclusion**

We demonstrate that the preferential PPAR-α activation via fenofibrate leads to neuroprotection by inhibiting neuroinflammation and protecting mitochondria in SOD1G93A mice. The significant improvement in survival with fenofibrate treatment in SOD1G93A mice provides evidence that it may be worthy of further development as a therapeutic strategy to block neurodegeneration in ALS.

**Materials and Methods**

**Mouse model of ALS**

**Animals**

All animal handling and experiments were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines of the University of Arkansas for Medical Sciences. Experiments employed hemizygous SOD1G93A (69) expressing mutant human SOD1, generated on a B6SJL background strain (G93A SOD1, B6SJL-TgGur1), Jackson Laboratories, Bar Harbor, ME, USA). Our colonies of these mice were housed in UAMS animal vivarium. Wild-type females (B6SJL/F1) were purchased from Jackson Laboratories to breed with SOD1G93A males. Animals were housed at room temperature in a 12 h light/dark cycle with free access to food and water. All procedures were reviewed and approved by the IACUC of University of Arkansas for Medical Sciences prior to starting the experiments for this study.

**SOD1G93A mice**

SOD1G93A mice overexpressing human SOD1 protein with mutations on glycine to alanine at position 93. These mice develop ALS-like phenotypes from the age of 85–90 days and progressively weaken, lose weight, develop asymmetrical hind-limb tremor and paralysis, gait abnormalities, muscle atrophy, impaired motor performance, forelimb paralysis at end-stage and premature death around 128 days of age. Pathologically, the affected spinal cords exhibit extensive loss of motor neurons, marked increase in gliosis.

**Fenofibrate treatment**

All the treatment cohorts of SOD1G93A mice were injected daily with fenofibrate (Sigma, St Louis, MO, USA) at 200 mg/kg of body weight starting at p40. Fenofibrate was dissolved in DMSO and made to 10% of the total volume injected. DMSO was used as in our previous study without any adverse effect (70).

**Mouse survival and motor function**

**Motor ability and weight assessment**

Motor performance was assessed using a rotarod apparatus (Harvard Panlab Rota-Rod apparatus, Holliston, MA, USA). This test measures the capability of mice to remain upright on the rod rotating at 12 rpm (rotations per minute). The time elapsed before a mouse falls off the rotarod measures its competency at the task and provides a reliable indication of motor performance and progression of motor dysfunction. All mice were trained twice in a week on the rotarod and subsequently tested bi-weekly from 60 days of age. Each mouse participated in three trials per test session (max 3 min), with the best result of three trials recorded. Mice were weighed twice a week.

**Survival**

Mice were observed each morning. Mice were deemed to have reached end-stage of the disorder when they can no longer initiate movement after being gently agitated for 2 min or cannot right themselves when placed on their backs within 20 s. These end stage mice were euthanized by CO2 overdose.

**Histology and immunohistochemistry**

Mice were deeply anesthetized with sodium pentobarbital and transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Spinal cords were removed, post-fixed with 4% paraformaldehyde for 2 h, washed with 1x PBS (phosphate buffered saline), cryoprotected in a graded series of 10, 20 and 30% sucrose, and cut into frozen serial 35 µm thick sections for immunohistochemical studies. Spinal cord tissue sections were stained for Nissl substance ( cresyl violet) as described elsewhere (71). Avidin–biotin–peroxidase method was performed for immunohistochemistry. Briefly, free-floating 35 µm thick spinal cord sections were treated with 3% H2O2 in 0.1 M PBS for 30 min. The sections were rinsed in PBS twice for 5 min each. Sections were incubated in 1% bovine serum albumin (BSA)/0.2% Triton X-100 (Sigma) for 30 min, then incubated overnight with primary antibodies (diluted in PBS/0.5% BSA) such as GFAP, (Dako, CA, USA), CD11b, PGC1-α and Cytochrome c (Santa Cruz Biotechnology, CA, USA). Biotinylated IgG secondary antibodies (diluted in PBS/0.5% BSA, Vector Laboratories, Burlingame, CA,
USA) were used for 1 h, and then incubated in avidin–biotin peroxidase complex (1:200 in PBS; Vector Laboratories) for 1 h. The immunoreaction was visualized using 3, 3′-diaminobenzidine tetrahydrochloridedihydrate (Vector Laboratories) as the chromogen. All incubations and rinses were performed at room temperature with agitation using an orbital shaker. The sections were mounted onto gelatin coated slides, dehydrated, cleared in xylene and cover slipped.

**Stereological cell counts**

Nissl-positive neurons were counted using standard procedures for stereological analysis as performed routinely in our laboratory as described elsewhere (71).

**Western blot analysis**

Expression levels of inflammatory genes such as iNOS and COX2 modulated by PPAR/RXR pathways were performed by the western blot analysis of tissue extracts from the spinal cord using standard procedures that are routinely performed in our laboratory. The β-actin was used as a house-keeping protein to normalize protein loading (n = 3 and representative of the replicate of three experiments presented).

**RNA isolation and qRT-PCR**

The total RNA was isolated from the spinal cord of fenuate and vehicle-treated SOD1G93A mice for in vivo transcriptional analysis. The total RNA was isolated according to manufacturer’s protocol using Trizol reagent (Invitrogen, CA, USA) and quantitated by ND-1000 NanoDrop (NanoDrop Technologies, DE, USA). The resultant 2.0 µg of total RNA was treated with ribonuclease free deoxyribonuclease (DNase1) (Ambion, TX, USA) to remove genomic DNA contamination and checked for DNA contamination by running a no-RT-PCR using GAPDH gene primers for 25 cycles in a thermocycler. RNA was stored in −80°C until further use. One microgram of DNase-treated RNA was used to make cDNA using the iScriptcDNA synthesis kit according to the manufacturer’s protocol (Bio-Rad, CA, USA). RT-PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) according to the kit instructions using the ABI Prism 7300 detection system (Applied Biosystems). Briefer, 100 ng of cDNA was subjected to an RT-PCR using gene-specific primers listed in Table 1. Cycling conditions were enzyme activation at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 15 s and annealing and extension at 60°C for 1 min. Dissociation steps were at 95°C for 15 s, 60°C for 30 s (including extension) and 95°C for 15 s. Relative expression levels were determined by the comparative threshold cycle (ΔΔCt) method using GAPDH as a reference gene (72). Below is the list of primer sequences for genes, analyzed in this study (n = 6 and representative of replicate of three experiments presented).

**Primer sequences for the gene expression analysis:**

**PPAR-α**

FWD: 5′-GTCTCCGAGTGTCTTCCAGGG-3′
REV: 5′-GGTCACTACAGGTGGGCGAT-3′

**PPAR-β**

FWD: 5′-GAGGGAGATGGAGACCTTG-3′
REV: 5′-AACAGGAGTGGTGGAGGAGA-3′

**PPAR-γ**

FWD: 5′-CTGTGAGACCAACAGCTGA-3′
REV: 5′-AATGCGAGTGGTCTTTCCATC-3′

**PGC1-α**

FWD: 5′-TGAGAGGCAGGAAGCAAAG-3′
REV: 5′-ATAATCACACCGGCCTTTT-3′

**NRF1**

FWD: 5′-TTGGCAAGAGTGGCTTTT-3′
REV: 5′-TTCTCTGGAAGGGAGAAGAT-3′

**TFAM**

FWD: 5′-AGCCAGGTCACCGCTAA-3′
REV: 5′-AAACCGAAGAAACGATG-3′

**SIRT1**

FWD: 5′-CTGCCGGCTCTTAACACAGGA-3′
REV: 5′-CTGCGGAGCCCTCAGACAG-3′

**SIRT3**

FWD: 5′-CTGCGGCTCTTAACACAGGA-3′
REV: 5′-CTGCGGAGCCCTCAGACAG-3′

**NQO-1**

FWD: 5′-CATTCTGAAGGCTGTTGAGA-3′
REV: 5′-CAGCTTTGATCTGTGTTGACG-3′

**HO-1**

FWD: 5′-ACATCGACACCCCCAAGATGTA-3′
REV: 5′-CTCGAAGAGTGACGGCATCTGTGAG-3′

**SOS-1**

FWD: 5′-AGCAGCTCGAAAAGGCCAGT-3′
REV: 5′-AAGCTACCTCTCGACCATC-3′

**SOS-3**

FWD: 5′-ACCAGGCCACACTTCCACG-3′
REV: 5′-CTGGAGACTCATCTGATCC-3′

**GSK3**

FWD: 5′-CAACAGGCAGAACAAATAGGAGAAAA-3′
REV: 5′-TGATGCAAGAGGGCCTTAT-3′

**iNOS**

FWD: 5′-TGGAGCCACAGGAAATATAGGAGAAA-3′
REV: 5′-AGCAGCTCGAAAAGGCCAGT-3′

**COX-2**

FWD: 5′-CAAACAGAAGCTGGCCGACATAC-3′
REV: 5′-GCCATGGCCTCTGCTGACTG-3′

**GAPDH**

FWD: 5′-ATCCAGAGCCTGAAAGC-3′
REV: 5′-GAAGTGGCAGGAGACA-3′

**Data analysis**

**Estimation of sample size**

Our experience with neurochemical measurements in previous animal experiments suggests that a standard deviation (SD) of 15–20% can be expected. Using the power analysis statistical program and our previous studies (73), we calculate that group sizes of 15–20 are adequate to give an 80% chance of detecting a 30% difference between groups. These results provide only estimates of sample sizes, and we predict requiring at least this number of samples to confidently exclude type II errors.

**Analysis of data**

Unless otherwise noted, data analysis was by analysis of variance and/or t-tests to compare sample groups, with a Bonferroni correction to correct for multiple comparisons if appropriate using the GraphPad Prism (GraphPad Software, CA, USA) InStat and Prism software. If data are not normally distributed (74), we used either the Mann–Whitney U-test or the Kruskal–Wallis test. Survival statistics were calculated from Kaplan–Meier survival curves using the Mantel–Cox log-rank analysis. The statistical significance was at the P < 0.05 level.

**Conflict of Interest statement.** None declared.
Funding
This work was supported by grants from UAMS startup fund, UAMS Center for Translational Neurosciences, and the National Institute of General Medical Sciences IDEA award P30 GM110702.

References


